Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Resumen
Palabras clave
Cáncer de mama; Supervivencia; Tucatinib
Citación recomendada
Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 Aug 10;38(23):2610–2619.
Audiencia
Professionals
Usar este identificador para citar y/o enlazar este documento
https://hdl.handle.net/11351/6230Este elemento aparece en las siguientes colecciones
- HVH - Articles científics [2896]
El ítem tiene asociados los siguientes ficheros de licencia: